In a recent enlightening discussion moderated by Dr. Anil Hingorani, two prominent figures in the field of venous procedures, Dr. Fedor Lurie and Dr. Lowell Kabnick, delved into the evolution of venous treatments, focusing on the groundbreaking EVOLVeS Study and its implications for the field.

The EVOLVeS Study, a milestone in venous research, marked the first randomized controlled trial comparing endovenous radiofrequency ablation to ligation and stripping. Dr. Kabnick expressed gratitude to Dr. Lurie and others for their contributions to this landmark study, which helped establish endovenous procedures worldwide.

The conversation touched upon the challenges faced during the trial, including patient preferences for endovenous procedures and resistance from the medical community to new technologies. Despite these obstacles, the study paved the way for advancements in venous treatments, shifting the standard of care from open surgery to minimally invasive techniques.

Dr. Lurie and Dr. Kabnick discussed the rapid evolution of venous procedures over the years, from the introduction of thermal ablation to the emergence of non-thermal technologies. They emphasized the importance of patient perspectives in shaping treatment options, highlighting the need for patient-friendly approaches in venous care.

Looking to the future, the discussion explored emerging trends in venous treatments, such as advancements in treating veins below the knee and the development of innovative technologies like non-thermal ablation. Dr. Lurie and Dr. Kabnick agreed that continued research and innovation are essential for addressing the evolving needs of patients with venous insufficiency.

In conclusion, the discussion highlighted the significant contributions of the EVOLVeS Study and the ongoing efforts of researchers and practitioners to improve venous care. By sharing insights and experiences, Dr. Lurie, Dr. Kabnick, and Dr. Hingorani provided valuable perspectives on the past, present, and future of venous procedures, shaping the landscape of vascular medicine for years to come.